No Data
Oppenheimer Maintains Atai Beckley(ATAI.US) With Buy Rating, Maintains Target Price $16
ATAI Life Sciences Files Prospectus for Share Resale
Press Release: Atai Life Sciences and Beckley Psytech Announce the Successful Completion of Their Strategic Combination to Create AtaiBeckley, a Global Leader in Transformative Mental Health Therapies
ATAI Life Sciences Approves Beckley Psytech Acquisition
Berenberg Bank Initiates ATAI Life Sciences(ATAI.US) With Buy Rating, Announces Target Price $12
ATAI Life Sciences: Promising Growth in Psychedelics Market With Strong Pipeline and Strategic Positioning